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doi:10.1016/j.ejvs.2010.09.020Abstract Ankle brachial index (ABI) is a simple method to screen peripheral arterial disease
(PAD) and to evaluate cardiovascular (CV) prognosis in the general population. Measuring it
requires a hand-held Doppler probe but it can be done also with an automatic device. ABI is
an effective tool for clinical practice or clinical studies. However, in diabetic patients, it
has some specific caveats. Sensitivity of the standard threshold of 0.9 appears to be lower
in diabetic patients with complications. Moreover, highly frequent arterial medial calcifica-
tions in diabetes increase ABI. It has been demonstrated that measurements >1.3 are well
correlated with both an increased prevalence of PAD and CV risk. Therefore, ABI thresholds
of less than 0.9 and more than 1.3 are highly suspicious for PAD and high CV risk in diabetic
patients. However, when there is concomitant clinical peripheral neuropathy or high risk of
arterial calcification, the efficiency of ABI seems to be limited. In this case, other methods
should be applied, toe pressure, in particular. Thus, the ABI could be used in patients with dia-
betes, but values should be interpreted with precision, according to the clinical situation.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Peripheral arterial disease (PAD) is a common manifestation
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ty for Vascular Surgery. PublisheCircumstances of discovery include intermittent claudica-
tion or distal trophic lesions, but some subjects are
asymptomatic, and the condition is detected during routine
physical examination.4
Introduced in the late 1960s, the measurement of the
ankle brachial index (ABI) is a simple test used to document
PAD in clinical and scientific settings. It is the ratio of systolic
pressures in the lower and upper extremities. Its current
pathological value is issued from older studies.5,6 Ever since,
a reduction in ABI is used as a strong indicator of PAD.7e10d by Elsevier Ltd. All rights reserved.
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severity of PAD,10,11 making it a widely used marker for the
presence and progression of PAD in major CV trials.12e16
Moreover, it has been reported that ABI is an independent
marker for CVmorbidity andmortality.17,18 These data apply
to the general population. Would it also be the case for
diabetic patients, who are known to have a higher incidence
of vascular complications? We conducted a systematic
review of use and utilities of ABI in patients with diabetes.
Methods
We searched the MEDLINE database since 1965 using
a combination of the following search terms: ‘ankle
brachial index’ and ‘diabetes’. Abstracts were systemically
reviewed and relevant articles obtained, based on the use
of ABI for diagnostic or prognostic purposes in a population
at least partially composed of patients with diabetes.
Reference lists of these articles were reviewed for addi-
tional studies.
Measurements of ABI
Measurement of ABI is made in the supine position after
5 min of rest. A pneumatic cuff is placed around the ankle
and the pressure is measured at both the dorsalis pedis and
posterior tibial arteries using a hand-held continuous-wave
Doppler probe (5e10 MHz). The same technique is also used
in both arms for measuring brachial artery pressure. The
higher of the two ankle pressures is divided by the brachial
artery pressure. In subjects with normal lower limb arterial
circulation, the systolic pressure at the ankle is usually
10e15 mmHg higher than that recorded from the arm
because of pulse wave velocity,19 resulting in an ABI >1.10.
Major international medical societies recommend calcu-
lating the ABI by dividing the highest pressure in the leg by
the highest pressure in the arm.20e22 Reproducibility of the
ABI measurement seemed to be good. In the ABI study, the
mean error of 8e9% within or between observers is smaller
than with established screening measures.23
PAD severity in each leg is assessed according to the
levels of ABI:
 0.91e1.30: normal;
 0.70e0.90: mild occlusion;
 0.40e0.69: moderate occlusion;
 <0.40: severe occlusion; and
 >1.30: poorly compressible vessels.
The American Diabetes Association recommends
measuring ABI in all diabetic patients older than 50 years or
in any patient suffering from PAD symptoms or having other
CV risk factors.22
Alternatives
Other options in measuring ABI are possible. The pressure
recordings can be used to test the effect of exercise. Nor-
mally, the ankle systolic pressure will not decrease with
moderate treadmill exercise. For patients in whom it is not
clear if the exercise-induced pain is due to arterial diseaseor other neuromuscular causes, it is necessary to perform
an exercise test.24
Methods of ABI calculation could also be different.
Indeed, several authors have estimated it using the lowest
values of ankle pressure. Schro¨der et al. compared low
(using the lowest value of ankle pressure) and high ABI
(using the highest one) to Doppler ultrasound (DUS). They
reported that the sensitivity and the specificity to diagnose
PAD when having an ABI <0.9 is 0.89e0.93 with lower ABI
values versus 0.68e0.99 with higher ones.25 In a recent
study, Espinola-Klein et al. showed that the use of low ABI
enhanced its use as a prognostic marker; the use of a high
value could exclude patients at high CV risk.26 However,
some authors recommend the use of the higher pressure
value for improved comparability of data in epidemiological
and clinical studies.27
The Doppler probe could be replaced by a standard
stethoscope or by an automatic device usually used for
routine blood pressure measurement at the arm. The use of
auscultation seems to be similar to the standard method;
however, the technique has not been widely investi-
gated.28,29 From another side, the use of an automated
blood pressure recorder seems to be a reliable, fast and
cost-effective method. It simply consists of measuring the
pressure by placing the cuff of the device on the same
anatomical sites used for Doppler. Several studies validated
the efficiency of ABI measuring using this method by
comparing it to standard reference techniques.30e32 Clair-
otte et al. evaluated this method in diabetic subjects and
showed that the results acquired with the automated
recorder strongly correlated to the ones obtained using
a DUS.33 Even though the global diagnostic performance of
this technique is slightly lower than in the case of Doppler,
it had the advantage of being more cost effective and easily
done by the medical team.
Thresholds
Recent publications reported that the interval between 0.9
and 1.10, currently taken as normal, may not be so.19
Actually, the value of 0.9 is somewhat arbitrary, as the
ABI is a continuous variable that indicates the severity of
the arterial occlusion. McDermott et al. reported that an
ABI between 0.90 and 0.99 or 1.00 and 1.09 was associated
with higher coronary or carotid artery stenosis than an
index between 1.10 and 1.30.34 In addition, a higher inci-
dence of intermittent claudication has been reported when
ABI values were within the lower normal range (0.90e0.99)
than in the upper normal one (1.10e1.40).35 In diabetic
patients, Clairotte et al. reported that the cut-off values
for the highest sensitivity and specificity for PAD screening
were between 1.0 and 1.1.33 Therefore, a normal low ABI
value could be sometimes the sign of an early or moderate
atherosclerotic process of lower limbs arteries.
ABI in patients with diabetes
PAD in diabetes
PAD is a diffuse atherosclerotic vascular disease frequently
present in diabetic patients. Its prevalence ranges between
9.5% and 13.6%36,37 in type 2 Diabetic (T2D) patients versus
112 L. Potier et al.4% in the general population.1 It has been shown that dia-
betes is the main risk factor for the occurrence of PAD.3
With every 1% increase in glycosylated haemoglobin
(HbA1c), there was a 28% increase in the risk of PAD in the
United Kingdom Prospective Diabetes Study (UKPDS).38
Although PAD is very common in patients with diabetes, it
remains grossly under-recognised in this type of pop-
ulation.39 Diagnosis is often difficult when diabetes is asso-
ciated with peripheral neuropathy because this last
condition couldmask the pain.36 Therefore, only one third of
diabetic patients with PAD have intermittent claudication.38
Paradoxically, some symptoms of painful diabetic neurop-
athy are sometimes mistaken for intermittent claudica-
tion.40 The association of both arteriopathy and neuropathy
is responsible for the high prevalence of wounds, ulcers and
amputations of diabetics’ feet.41
PAD in patients with diabetes show some specific
aspects. Contrary to PAD in smokers, arteriopathy in dia-
betic patients is known to involve distal arteries more than
proximal ones. The main vessels affected are the popliteal
artery, anterior tibioperoneal trunk, posterior tibial and
dorsalis pedis.22,42 Moreover, there is a strong association
between diabetes and medial artery calcification (MAC).43
This last condition causes arterial wall stiffness, which
results in high pressure ankle, and thus a high ABI. MAC is
often associated with peripheral neuropathy and to chronic
renal failure (CRF).44 In addition, an ABI >1.3 in CRF is
frequently associated with hyperparathyroidism, suggesting
a possible role of the disturbances in calcium and phos-
phorus metabolism in the occurrence of MAC.45
Do these specific PAD data in diabetic patients represent
an obstacle to the extrapolation of the criteria of ABI use
that are valid for the general population?
Screening and diagnosis of ABI in diabetic patients
Using DUS as a reference method, William et al. showed in
a group of diabetic patients with an intermediate vascular
profile and without neuropathy that an ABI <0.9 had
a sensitivity of 100% and a specificity of 88%. The results in
the non-diabetic control group were almost similar (sensi-
tivity 83% and specificity 100%).46 Alnaeb et al. reported
a correlation of 0.81 between an ABI <0.9 and arterial
DUS in the same type of diabetic patients.47 These results
are in favour of the use of ABI as a screening test or
a diagnostic tool in patients with diabetes (Table 1).
However, can this diagnostic efficiency of ABI be applied
in all types of diabetic patients? In a recent study thatTable 1 Mean, Sensibility and specificity of ABI using the thresh
CV risk and/or no neuropathy.
Study Number of patients/lower
limbs
Characteristics o
patientsa
Parameswaran
GI 2005
57 patients/114 limbs Intermediate CV
Williams DT 2005 25 limbs Intermediate CV
no neuropathy,
Alnaeb ME 2007 47 limbs Intermediate CV
NC : Not communicated.
a Estimation of cardiovascular (CV) risk is based on prevalence of t
specified.evaluated patients who had undergone both ABI measure-
ments and angiography, Chung et al. showed that the most
influential factor affecting the validity of ABI was diabetes,
with an odds ratio (OR) of 4.36 for the false negative results
taken as a primary end point.48 Indeed, several studies
showed that the decrease of the diagnostic efficiency of ABI
is related to certain clinical situations related to diabetes
such as neuropathy or foot wounds.49e51 For instance, the
sensitivity of ABI falls to 53% (specificity 95%) in the presence
of peripheral neuropathy.46 In patients with an advanced
vascular profile, an ABI<0.9 had 54.4% sensitivity in diabetic
versus 72.6% in non-diabetic patients when comparing it to
DUS.34
This decrease in ABI sensitivity can also be explained by
arterial stiffness secondary to MAC. This results in poorly
compressible vessels and a high ABI. Indeed, high index
values (>1.3e1.4) are particularly frequent in diabetic
patients,17,52 more specifically when diabetes is concomi-
tant to kidney disease, neuropathy or foot lesions.53 In this
case, high ABI values and MAC correlate with the duration
and severity of diabetes.54,55 Therefore, the sensitivity of
ABI seems to be limited in case of complicated or long-
standing diabetes leading to more MAC. Moreover, high ABI
could underestimate the prevalence of PAD in diabetes
because ABI values between 0.9 and 1.3 would be falsely
considered as normal and higher values could not be inter-
preted. Indeed, the prevalence of PAD measured with DUS
was 57% in diabetic patientswith high CV risk and neuropathy
whereas ABI was between 0.9 and 1.3.56 Other authors also
reported a high prevalence of PAD in diabetic patients with
elevated ABI values, estimated between 58% and 84%.57,58 It
is thought that the association between high ABI values and
PAD is due to the fact that arterial stiffness is associatedwith
a decrease in bloodstream in the lower limbs of diabetic
patients.59 Furthermore, high ABI values in diabetes could be
indicative of PAD. In a recent report of the National Health
and Nutrition Examination Survey, the presence of a PAD is
not only defined by an ABI <0.9 but also with values >1.4.60
In this case, a duplex ultrasound examination must be per-
formed to confirm and evaluate PAD.
The diagnostic efficiency of ABI as a screening test may be
limited indiabetic patientswithelevatedCVrisk, neuropathy,
nephropathy and foot lesions, because of its weak sensitivity
and the high rate of biased normal values (Table 2), probably
due to the high prevalence of MAC. One way to improve the
diagnostic efficiency of ABImight be to use a higher threshold,
around 1e1.1 or to use the lowest value of ankle systolicold of 0.9 in population of diabetic patients with intermediate
f Mean
ABI
Method of
reference
Sensibility
(%)
Specifity
(%)
risk NC Doppler ultrasound 63 97
risk,
no PAD
1.06 Doppler ultrasound 100 88
risk 0.84 Doppler ultrasound 80 93
raditional risk factors, diabetes duration, and mean HbA1c when
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Brooks et al. showed that toe-pressure measurement was
more sensitive than ABI.61 In the sameway, in the presence of
clinical peripheral neuropathy (defined using International
Consensus on the Diabetic Foot (ICDF) guidelines), toe pres-
sure sensitivity was 100% but was only 53% for ABI.46 Hence, in
some clinical situations with high risk of MAC (clinical
neuropathy, nephropathy and long duration of diabetes), ABI
should be interpreted carefully, and normal values are not
sufficient to rule out the diagnosis of PAD. Other methods,
such as toe-pressure measurements, because arteries at the
level of theankleweremore frequently calcified than those at
the toe level, are recommended because of their excellent
sensitivity. Further studies are required to provide more
specific recommendations.
Prognostic values
Besides its usage for diagnosing and evaluating the severity of
PAD, ABI has an independent and important value in esti-
mating global vascular prognosis. A decreased ABI is a major
risk factor of CV morbidity and mortality.17,62 This prognostic
value is also valid for diabetic patients.63,64 The Fremantle
diabetes study showed that in T2D, an ABI0.9 increased the
riskofcardiacdeathby67%.37 Jue Lietal. reportedthatanABI
lower than 0.9 increased significantly the adjusted relative
risk of CV mortality in a Chinese population of T2D; addi-
tionally, the risk was inversely correlated to the decrease in
ABI.65 During a follow-up of 14 years in elderly Swedish dia-
betic patients, the rate of cardiac events was reported to be
as high as 102 for 1000 patients year1 with an ABI<0.9 versus
28.4 when the ABI is within the normal range.66
High ABI values (above the normal range) could also be
an indicator of CV system damage. Earlier, in the 1980s,
Everhart et al. showed that MAC increased the risk of
mortality in T2D by a factor of 1.5.55 Similar data were
reported in a diabetic veteran population.67 In a recent
subanalysis of the Strong Heart Study, Resnick et al. showed
that any increase of ABI above 1.4 was an independent CV
risk factor. There was a U-shape association between ABI
value and CV mortality.52 Indeed, the adjusted risk for CVTable 2 Mean, Sensibility and specificity of ABI using the thresh
neuropathy or foot ulcer.
Study Number of patients/
lower limbs
Characteristics of
patientsa
Janssen A
2005
106 patients/
140 limbs
Neuropathyc
Williams DT
2005
57 limbs Neuropathyb
Potier L
2009
83 patients/
162 limbs
High CV risk
Clairotte C
2009
166 limbs High CV risk
Premalatha G
2002
100 patients Foot ulcer
NC: Not communicated.
a Estimation of cardiovascular (CV) risk is based on prevalence of t
communicated.
b Neuropathy was defined using ICDF guidelines.
c No definition of neuropathy was specified.mortality was 2.52 with an ABI <0.9 and 2.09 with an ABI
>1.4. This association was positive in diabetic patients,
who represented 67.8% of patients with a high ABI >1.4. An
increased ABI reflects also coronary calcifications, sug-
gesting that elevation of this index could reflect diffuse
atheromatous disease.68,69
In the Fremantle Diabetes study, an ABI <0.9 is an
independent risk factor for amputation with a relative risk
of 2.21.41 In the same way, elevated ABI value increased
the risk of amputation by 5.5.55
Thus, not only low, but also high ABI values are prog-
nostic of CV risk as well as the risk of occurrence of foot-
related injuries and amputations. ABI provides information
regarding the distribution of atherosclerotic disease.
ABI and microangiopathy in diabetes
Nephropathy
Diabetic nephropathy at the early stage of microalbuminuria
may be an early sign of intrarenal vascular dysfunction and
a marker of atherosclerotic disease. However, what is the
relative impact of albuminuria and glomerular filtration rate
(GFR) on ABI in diabetes?
Available data in the diabetic population were in favour of
a lowABI in caseof renal failure.70,71 In a recent analysis of the
National Health and Examination Survey,Wuet al. studied the
relationship betweenPAD,definedas anABI<0.9 or>1.4, and
renal failure and/or microalbuminuria in 7068 subjects of
whom 1156 were diabetics.72 The presence of abnormal renal
function, as estimated by a GFR <60 ml1 min 1.73 m2 was
strongly associatedwith PAD in the diabetic patients (OR 2.3),
whereas there was no significant association in the non-dia-
betic patients. Paradoxically, a urinary albumin/creatinine
ratio30mgg1,was independently associatedwith PADonly
in non-diabetic individuals (OR 1.87). However, the Multi-
Ethnic Study of Atherosclerosis showed in diabetic patients
that the presence of albuminuria increases the risk of an ABI
<0.9 by 90% and by 65% after further adjustment formajor CV
risk factors.73 Moreover, in another Taiwanese study, the
prevalenceofanABI<0.9 inelderlyT2Dpatientswas 8.0, 17.1old of 0.9 in population of diabetic patients with high CV risk,
Mean ABI Method of reference Sensibility
(%)
Specifity
(%)
NC Arterial angiography 71 30
1.21 Doppler ultrasound 53 95
0.9 Doppler ultrasound 50 79.6
1.01 Doppler ultrasound 54.4 96.8
NC Doppler ultrasound 70.6 88.5
raditional risk factors, diabetes duration, and mean HbA1c when
114 L. Potier et al.and 38.5%, according to the presence of normo-, micro- and
macroalbuminuria, respectively.74
The decrease of GFR is strongly associated with low and
high ABI in diabetic patients. Nevertheless, the impact of
micro- or macroalbuminuria on the values of ABI is not so
clear and requires further studies.
Neuropathy and retinopathy
Limited available data regarding the association of diabetic
neuropathy and retinopathy with ABI support a higher prev-
alence of these microvascular complications in case of
abnormal ABI values.75 High ABI is more often noticed in case
of neuropathy.44,53 This observation could be explained by
the role of neuropathy in the pathophysiology of MAC. In
fact, sympathectomy of lower limbs causes major arterial
calcification years later, through a mechanism that is not
well understood.76,77 Some other studies showed a correla-
tion between the presence of MAC and microalbuminuria or
retinopathy.44,78 Thus, Everhart et al. showed that diabetic
patientswithMAChad a risk of 2.4 to develop proteinuria and
of 1.7 to develop retinopathy.55
However, it is difficult to draw conclusions and estab-
lish a causal relationship between arteriopathy as sug-
gested by an abnormal ABI and diabetic microangiopathy.
These observations could probably be the simple reflec-
tion of the severity of diabetes: the more severe it is
(long duration and poor glycaemic control), the higher is
the prevalence of microvascular complications as reflec-
ted by MAC. Some data are in favour of a causal relation
between high ABI secondary to MAC and microangiopathy.
In this case, would these abnormally high values be an
indicator for renal and neurological damage? To our
knowledge, there are no data about this issue. Specific
studies are required to understand clearly the link
between the increase of ABI and microvascular compli-
cation of diabetes.Conclusion
The measurement of ABI is a simple and reliable method
that has proven to be efficient in diagnosing PAD and esti-
mating CV risk in diabetes. Even when it is assessed using
non-conventional methods, such as in the case of an auto-
matic device, it remains an acceptably sensitive test in
primary care or clinical studies.
ABI values <0.9 are conventionally used as a pathological
threshold to define PAD and high CV risk. However, the
sensitivity of this threshold appears to be lower in compli-
cated T2D, particularly in the presence of clinical peripheral
neuropathy. In this case, other tests with a higher sensitivity,
such as toe blood pressure, should be performed.
Furthermore, a high ABI, which is a marker of MAC, is
often associated with neuropathy and/or chronic kidney
disease. These unreliable high values seem to be the
marker of a particular form of PAD with more diffused
atherosclerosis or even microvascular damage. Because of
the high risk of amputation, special attention should be
accorded to patients with such a profile.
Thus, ABI can be used in diabetic patients because of its
simplicity, but values obtained should be interpreted with
caution, according to the clinical situation.Conflict of Interest
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